New data from Medtronic's (Minneapolis) Adaptive CRT trial show a 61% lower risk of atrial fibrillation (AF)-related problems in patients who receive a cardiac resynchronization therapy-defibrillator (CRT-D) with the Medtronic-exclusive AdaptivCRT algorithm compared to conventional biventricular pacing therapy. The data also indicate a 55% relative reduction in healthcare utilizations (HCUs, including hospitalizations, emergency department or clinic visits) when patients have devices with AdaptivCRT.